Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-Label, Multicenter, Prospective Clinical Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous Non-small Cell Lung Cancer

NCT04507217 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT04507217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04507217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-Label, Multicenter, Prospective Clinical Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous Non-small Cell Lung Cancer
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Completed
Start date
September 15, 2020
Completion date
January 30, 2023
Enrollment
36 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, nsclc stage iv, pd-1 antibody